{"id":"W3207786785","doi":"10.1016/j.jtho.2021.09.010","title":"First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Cilag; Janssen Pharmaceuticals; Sandoz; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Ipsen; Teijin Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; Clovis Oncology; AstraZeneca; Novocure; Merck KGaA; Taiho Pharmaceutical; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Johnson and Johnson; Teva Pharmaceutical Industries; Servier; Bayer; Gilead Sciences; Sanofi; University of Pennsylvania; Celgene; Novartis; GlaxoSmithKline; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Adverse effect; Confidence interval; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003113187,0.0002498945,0.002053243,0.0001199378,0.0001182719,0.0000653505,0.0004743521,0.0002360919,0.001311553],"category_scores_gemma":[0.001390157,0.000152499,0.0004177699,0.0003558708,0.0002249206,0.0002331581,0.000153503,0.0007236616,0.00001885748],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006582469,"about_ca_system_score_gemma":0.001614178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001286777,"about_ca_topic_score_gemma":0.0005629546,"domain_scores_codex":[0.9964158,0.0009412151,0.001616414,0.0002811911,0.0003978524,0.0003475178],"domain_scores_gemma":[0.9962736,0.001776279,0.001066372,0.000446923,0.0002947806,0.0001420695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8788446,0.001930773,0.0001118817,0.00002141471,0.0008093906,0.0008252375,0.0004894265,0.00001643688,0.001477813,0.00001132683,0.003279408,0.1121823],"study_design_scores_gemma":[0.8965654,0.003402134,0.0003185972,0.0004061149,0.0005983154,0.0002815522,0.000723463,0.0001458401,0.001310463,0.0003212297,0.0957609,0.0001660251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9517897,0.006451173,0.0001860965,0.03439502,0.004023168,0.00142858,0.00003901301,0.00001454836,0.001672737],"genre_scores_gemma":[0.9741958,0.007934226,0.005194815,0.006582939,0.001990994,0.0001253776,0.00005297332,0.00006904254,0.003853774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1120162,"threshold_uncertainty_score":0.9996014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06623119738577873,"score_gpt":0.4494461952160643,"score_spread":0.3832149978302856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}